728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals

BACKGROUND: Antibiotic-resistant Gram-negative bacteria, including KPC-producing Enterobacteriaceae and carbapenem-resistant A. baumannii, have been problematic hospital pathogens in NYC and other areas. Eravacycline (ERV), a fluorocycline antibiotic released in the USA in 2018, has demonstrated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Iregui, Alejandro, Khan, Zeb, Landman, David, Quale, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811199/
http://dx.doi.org/10.1093/ofid/ofz360.796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811199/
http://dx.doi.org/10.1093/ofid/ofz360.796

Ejemplares similares